Exhibitor Details

Back

RAJAT CARE LLP

PLOT NO. 1, LS. NO. 13/1, DHORAJI-JETPUR NATIONAL HIGHWAY, DHORAJI
WWW.RAJATCARE.COM

Product Categories

Formulations
ACECLOFENAC (100 MG)+ PARACETAMOL (325 MG),ARTEETHER (20 MG) + LUMEFANTRINE (120 MG),ARTEETHER (40 MG) + LUMEFANTRINE (480 MG),ARTEMETHER (180 MG) + LUMEFANTRINE (1080 MG),ARTEMETHER (80 MG) + LUMEFANTRINE (480 MG),ATORVASTATIN (20 MG),ATORVASTATIN (40 MG),ATORVASTATIN (80 MG),AZITHROMYCIN (250 MG),CIPROFLOXACIN (500 MG),DAPAGLIFLOZIN (10 MG) + SITAGLIPTIN (100 MG),DAPAGLIFLOZIN (5 MG) + TENELIGLIPTIN (20 MG),DICYCLOMINE (10 MG) + DICLOFENAC (250 MG),DICYCLOMINE (10 MG) + MEFENAMIC ACID (250 MG),DOMPERIDONE (30 MG) + PANTOPRAZOLE (40 MG),EMPAGLIFLOZIN (10 MG) + LINAGLIPTIN (5 MG) + METFORMIN (1000 MG),GLIMEPIRIDE (1 MG) + METFORMIN (1000 MG),ITRACONAZOLE (10 MG),LEVOFLOXACIN (500 MG),MONTELUKAST (10 MG) + LEVOCETIRIZINE (5 MG),ROSUVASTATIN (40 MG),SILDENAFIL (100MG),Tadalafil(10mg),Tadalafil(20mg),TELMISARTAN (40 MG),TELMISARTAN (40 MG) + AMLODIPINE (10 MG),TELMISARTAN (40 MG) + AMLODIPINE (5 MG)

Company Profile

RAJAT CARE LLP IS A PHARMACEUTICAL MANUFACTURING COMPANY FOCUSED ON THE PRODUCTION OF HIGH-QUALITY NON-BETA-LACTAM TABLETS AND CAPSULES FOR DOMESTIC AND INTERNATIONAL MARKETS. AS PART OF THE RAJAT GROUP, THE COMPANY OPERATES A MODERN, WHO-GMP-COMPLIANT MANUFACTURING FACILITY EQUIPPED WITH ADVANCED, USFDA-COMPLIANT TECHNOLOGY AND SYSTEMS ALIGNED WITH 21 CFR PART 11 REQUIREMENTS. RAJAT CARE HAS DEDICATED PRODUCTION, QUALITY CONTROL, MICROBIOLOGY, R&D AND STABILITY FACILITIES, SUPPORTED BY ADVANCED EQUIPMENT AND AUTOMATED MANUFACTURING PROCESSES. THE FACILITY HAS SUBSTANTIAL MANUFACTURING CAPACITY FOR TABLETS AND CAPSULES AND IS DESIGNED TO MEET STRINGENT QUALITY AND REGULATORY STANDARDS. WITH A STRONG FOCUS ON QUALITY, COMPLIANCE, INNOVATION AND CUSTOMER SATISFACTION, RAJAT CARE AIMS TO BECOME A TRUSTED CONTRACT MANUFACTURING AND EXPORT PARTNER FOR PHARMACEUTICAL COMPANIES WORLDWIDE, SERVING MARKETS ACROSS AFRICA, LATIN AMERICA, THE MIDDLE EAST AND OTHER EMERGING MARKETS.